Tag: Pixium Vision

Pixium Vision announces the availability of itsaudited financial statements for the financial year 2021   Paris, 29 April 2022 – 7.00 p.m. CET - Pixium Vision SA (Euronext Growth Paris - ...

Pixium Vision announces FDA approval of clinical trial expansion of Prima System US feasibility study to Stanford Medicine FDA approves new additional study location at Stanford Medicine Paris, France, January ...

Pixium Vision to participate in the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest on March 28 - 30 Paris, France, March 24, 2022 – ...

Pixium Vision convenes a Combined General Meeting of Shareholders on April 19, 2022 Paris, France, March 14, 2022 – 19:00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ...

        Pixium Vision announces its unaudited financial results for 2021 and provides a business update Cash position on 31 December 2021: €14.5 millionCash runway to end of Q4 2022Clinical development, activating ...

Pixium Vision to attend 11th Annual LifeSci Partners Corporate Access Event CEO Lloyd Diamond to participate in a panel discussion on “Med Tech / Digital Tools: What’s the Mindset for ...

Pixium Vision gaining confidence in execution timeline of the PRIMAvera pivotal trial following first patient implantation in the UK Successful implantation of the first patient in the PRIMAvera study in ...

Pixium Vision to present at BTIG’s Ophthalmology Day Paris, France, November 25, 2021 – 07.00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative ...

Pixium Vision to present at the 3rd edition of Investir Day in Paris, November 2021 Paris, France, 8 November 2021 – 7:00 a.m. CET– Pixium Vision SA (Euronext Growth Paris ...

      Pixium Vision announces its cash position at 30 September 2021 and provides an update on its activities and financial outlook until the end of 2022. Paris, 22 October 2021 – ...